Core Viewpoint - North China Pharmaceutical has received approval for two products: Vitamin B6 injection and injectable Isavuconazole, indicating a strategic expansion in both essential vitamins and high-end anti-infection markets [1][2][3] Group 1: Product Approvals - The company has been granted a supplementary approval for Vitamin B6 injection (1ml: 100mg) and a drug registration certificate for injectable Isavuconazole (0.2g) by the National Medical Products Administration [1][2] - Vitamin B6 is widely used in clinical settings for various metabolic disorders, with its indications expanding due to ongoing research [1] - The sales data from 2020 to 2023 shows fluctuations in Vitamin B6 injection sales, with a peak of 62.02 million yuan in 2021 and a decline to 46.37 million yuan in 2023 [1] Group 2: Market Strategy - The company plans to leverage its production and sales resources to expand sales channels and increase market coverage following the approval of the new Vitamin B6 injection specification [2] - North China Pharmaceutical aims to participate actively in national and provincial alliance procurement initiatives [2] - The company is considering further product pipeline development in the B vitamin sector based on market trends and strategic goals [2] Group 3: Financial and Competitive Position - The cumulative R&D investment for injectable Isavuconazole is reported to be 15.27 million yuan, and the product is expected to enhance the company's product line in the anti-infection sector [3] - The approval of Isavuconazole signifies the company's entry into the high-end anti-infection market, potentially providing new revenue growth opportunities [3] - The presence of five companies in the domestic market holding registration for injectable Isavuconazole indicates a competitive landscape, with the product achieving sales of 100 million yuan in 2023 [2][3]

Market Overview - The micro-cap stock index rose over 2% during the morning session, while the three major indices experienced slight declines [1] - The total trading volume in the Shanghai and Shenzhen markets reached 707.5 billion, an increase of 41.8 billion compared to the previous trading day [1] - A total of 2,900 stocks in the market saw gains, indicating a broad-based upward movement [1] Sector Performance - Mergers and acquisitions, as well as ST stocks, saw significant gains, with companies like Guangzhi Technology hitting the daily limit [1] - Port and shipping stocks strengthened again, with Lianyungang also reaching the daily limit [1] - Controlled nuclear fusion concept stocks maintained strong performance, with Wangzi New Materials hitting the daily limit [1] - In contrast, the robotics sector faced adjustments, with Longxi Co. hitting the daily limit down [1] Index Performance - By the end of the session, the Shanghai Composite Index fell by 0.09%, the Shenzhen Component Index decreased by 0.36%, and the ChiNext Index dropped by 0.53% [1] Limit-Up Performance - The limit-up rate was recorded at 78%, with 60 stocks hitting the limit and 17 stocks touching the limit [4] - The opening rate was 77%, and the profit rate stood at 66% [4]